[go: up one dir, main page]

AR110979A1 - CD70 BINDING MOLECULES AND SAME USE METHODS - Google Patents

CD70 BINDING MOLECULES AND SAME USE METHODS

Info

Publication number
AR110979A1
AR110979A1 ARP180100350A ARP180100350A AR110979A1 AR 110979 A1 AR110979 A1 AR 110979A1 AR P180100350 A ARP180100350 A AR P180100350A AR P180100350 A ARP180100350 A AR P180100350A AR 110979 A1 AR110979 A1 AR 110979A1
Authority
AR
Argentina
Prior art keywords
seq
cdr
amino acid
acid sequence
chain variable
Prior art date
Application number
ARP180100350A
Other languages
Spanish (es)
Original Assignee
Kite Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kite Pharma Inc filed Critical Kite Pharma Inc
Publication of AR110979A1 publication Critical patent/AR110979A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un polinucleótido aislado que codifica un receptor de antígeno quimérico (CAR) o receptor de célula T (TCR) que comprende una molécula de unión a antígeno que se une específicamente a CD70, en donde la molécula de unión a antígeno comprende: (a) una región determinante de complementariedad (CDR) 1 de región variable de cadena pesada (VH) que comprende, consiste o consiste esencialmente en una secuencia de aminoácidos seleccionada del grupo integrado por GFTFSSY (SEQ ID Nº 71), GDSIISGGY (SEQ ID Nº 73) y GYTFTSY (SEQ ID Nº 75); (b) una región determinante de complementariedad (CDR) 2 de región variable de cadena pesada (VH) que comprende, consiste o consiste esencialmente en una secuencia de aminoácidos seleccionada del grupo integrado por WYDGSN (SEQ ID Nº 72), FYSGS (SEQ ID Nº 74) y DPSGGS (SEQ ID Nº 76); (c) una región determinante de complementariedad (CDR) 3 de región variable de cadena pesada (VH) que comprende, consiste o consiste esencialmente en una secuencia de aminoácidos seleccionada del grupo integrado por DLLRGVKGYAMDV (SEQ ID Nº 64), SGYSYALFDH (SEQ ID Nº 67) y DYGDYVFDY (SEQ ID Nº 76); (d) una región determinante de complementariedad (CDR) 1 de región variable de cadena ligera (VL) que comprende, consiste o consiste esencialmente en una secuencia de aminoácidos seleccionada del grupo integrado por RASQSLRRIYLA (SEQ ID Nº 53), RASQFIGRYFN (SEQ ID Nº 56) y SGSSSNIGTNTVN (SEQ ID Nº 59); (e) una región determinante de complementariedad (CDR) 2 de región variable de cadena ligera (VL) que comprende, consiste o consiste esencialmente en una secuencia de aminoácidos seleccionada del grupo integrado por DVFDRAT (SEQ ID Nº 54), AESSLQS (SEQ ID Nº 57) e INNQRPS (SEQ lD Nº 60); (f) una región determinante de complementariedad (CDR) 3 de región variable de cadena ligera (VL) que comprende, consiste o consiste esencialmente en una secuencia de aminoácidos seleccionada del grupo integrado por QQYSDSPFT (SEQ ID Nº 55), QQSYSTPFT (SEQ ID Nº 58) y ATWDDSLNGPW (SEQ ID Nº 61). Reivindicación 60: Un vector que comprende el polinucleótido de cualquiera de las reivindicaciones 1 a 59. Reivindicación 63: Una célula que comprende el polinucleótido de cualquiera de las reivindicaciones 1 a 59, el vector de la reivindicación 60 ó 61, el CAR o TCR de la reivindicación 62, o cualquier combinación de estos. Reivindicación 68: Una composición que comprende el polinucleótido de cualquiera de las reivindicaciones 1 a 59, el vector de la reivindicación 60 ó 61, el CAR o TCR de la reivindicación 62, o la célula de cualquiera de las reivindicaciones 63 a 67. Reivindicación 73: Un método para tratar un cáncer en un sujeto que lo necesita, que comprende administrar al sujeto el polinucleótido de cualquiera de las reivindicaciones 1 a 59, el vector de la reivindicación 60 ó 61, el CAR o TCR de la reivindicación 62, la célula de cualquiera de las reivindicaciones 65 a 67, o la composición de la reivindicación 68 ó 69.Claim 1: An isolated polynucleotide encoding a chimeric antigen receptor (CAR) or T cell receptor (TCR) comprising an antigen binding molecule that specifically binds to CD70, wherein the antigen binding molecule comprises: ( a) a complementarity determining region (CDR) 1 of heavy chain variable region (VH) comprising, consisting or consisting essentially of an amino acid sequence selected from the group consisting of GFTFSSY (SEQ ID No. 71), GDSIISGGY (SEQ ID No. 73) and GYTFTSY (SEQ ID No. 75); (b) a complementarity determining region (CDR) 2 of heavy chain variable region (VH) comprising, consisting or consisting essentially of an amino acid sequence selected from the group consisting of WYDGSN (SEQ ID No. 72), FYSGS (SEQ ID No. 74) and DPSGGS (SEQ ID No. 76); (c) a complementarity determining region (CDR) 3 of heavy chain variable region (VH) comprising, consisting or consisting essentially of an amino acid sequence selected from the group consisting of DLLRGVKGYAMDV (SEQ ID No. 64), SGYSYALFDH (SEQ ID No. 67) and DYGDYVFDY (SEQ ID No. 76); (d) a complementarity determining region (CDR) 1 of a light chain variable region (VL) comprising, consisting or consisting essentially of an amino acid sequence selected from the group consisting of RASQSLRRIYLA (SEQ ID No. 53), RASQFIGRYFN (SEQ ID No. 56) and SGSSSNIGTNTVN (SEQ ID No. 59); (e) a complementarity determining region (CDR) 2 of a light chain variable region (VL) comprising, consisting or consisting essentially of an amino acid sequence selected from the group consisting of DVFDRAT (SEQ ID No. 54), AESSLQS (SEQ ID No. 57) and INNQRPS (SEQ ID No. 60); (f) a complementarity determining region (CDR) 3 of a light chain variable region (VL) comprising, consisting or consisting essentially of an amino acid sequence selected from the group consisting of QQYSDSPFT (SEQ ID No. 55), QQSYSTPFT (SEQ ID No. 58) and ATWDDSLNGPW (SEQ ID No. 61). Claim 60: A vector comprising the polynucleotide of any one of claims 1 to 59. Claim 63: A cell comprising the polynucleotide of any of claims 1 to 59, the vector of claim 60 or 61, the CAR or TCR of claim 62, or any combination thereof. Claim 68: A composition comprising the polynucleotide of any one of claims 1 to 59, the vector of claim 60 or 61, the CAR or TCR of claim 62, or the cell of any of claims 63 to 67. Claim 73 : A method of treating a cancer in a subject in need thereof, comprising administering to the subject the polynucleotide of any one of claims 1 to 59, the vector of claim 60 or 61, the CAR or TCR of claim 62, the cell of any of claims 65 to 67, or the composition of claim 68 or 69.

ARP180100350A 2017-02-14 2018-02-14 CD70 BINDING MOLECULES AND SAME USE METHODS AR110979A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762458879P 2017-02-14 2017-02-14

Publications (1)

Publication Number Publication Date
AR110979A1 true AR110979A1 (en) 2019-05-22

Family

ID=61283393

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100350A AR110979A1 (en) 2017-02-14 2018-02-14 CD70 BINDING MOLECULES AND SAME USE METHODS

Country Status (7)

Country Link
US (2) US11046775B2 (en)
EP (2) EP3583129B1 (en)
AR (1) AR110979A1 (en)
ES (1) ES2900233T3 (en)
PT (1) PT3583129T (en)
TW (3) TW202344517A (en)
WO (1) WO2018152181A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112020518A (en) * 2018-02-01 2020-12-01 辉瑞公司 Chimeric Antigen Receptor Targeting CD70
KR102768098B1 (en) 2018-02-01 2025-02-17 화이자 인코포레이티드 Antibodies specific for CD70 and uses thereof
SG11202007622SA (en) * 2018-02-11 2020-09-29 Memorial Sloan Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof
US20200003758A1 (en) 2018-06-01 2020-01-02 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
CN110818802B (en) * 2018-08-08 2022-02-08 华夏英泰（北京）生物技术有限公司 Chimeric T cell receptor STAR and application thereof
CN109880802B (en) * 2018-11-30 2022-12-13 北京美康基免生物科技有限公司 A CD19 and CD70-based dual chimeric antigen receptor genetically modified immune cell and its application
US20220047634A1 (en) * 2018-11-30 2022-02-17 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptor factories and methods of use thereof
CN113646426B (en) * 2019-04-04 2024-09-13 上海医药集团股份有限公司 Immune cell containing tumor antigen recognition receptor and application thereof
EP4031150A4 (en) * 2019-09-16 2023-11-01 The General Hospital Corporation Cd70 targeted chimeric antigen receptor (car) t cells and uses thereof
KR20230020421A (en) * 2020-05-05 2023-02-10 티씨알2 테라퓨틱스 인크. Compositions and methods for TCR reprogramming using CD70 specific fusion proteins
WO2022104109A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
AU2021388155A1 (en) 2020-11-25 2023-06-15 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
US20240024475A1 (en) * 2020-12-01 2024-01-25 Cure Genetics Co., Ltd Antigen-Binding Protein Targeting CD70 and Use Thereof
CA3201115A1 (en) 2020-12-21 2022-06-30 Shanshan LANG Protease-activating cd45-gate car
MX2023008809A (en) 2021-01-29 2023-08-04 Allogene Therapeutics Inc KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, ß2m, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS.
CN116023500B (en) * 2021-10-25 2023-07-04 重庆精准生物技术有限公司 Chimeric antigen receptor targeting fully humanized CD70 and application thereof
CN116023490B (en) * 2021-10-25 2023-08-25 重庆精准生物技术有限公司 Antigen binding fragments and single chain antibodies targeting CD70 and uses thereof
AU2023312973A1 (en) 2022-07-29 2025-01-09 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024153016A1 (en) * 2023-01-16 2024-07-25 上海华奥泰生物药业股份有限公司 Antibody targeting cd70 or antigen binding fragment binding to cd70, and preparation method therefor and use thereof
WO2024236547A1 (en) 2023-05-18 2024-11-21 Inceptor Bio, Llc Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
US20240398982A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69127627T2 (en) 1990-08-29 1998-02-19 Genpharm Int Production and Use Non-human transgene heterologous antibodies for production
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE122004000008I1 (en) 1991-06-14 2005-06-09 Genentech Inc Humanized heregulin antibody.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
EP1257632B1 (en) 2000-02-24 2007-09-12 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
EP2298809A3 (en) 2001-07-12 2012-02-15 FOOTE, Jefferson Super humanized antibodies
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN103442768A (en) 2011-01-18 2013-12-11 宾夕法尼亚大学董事会 Compositions and methods for treating cancer
AU2012230780B2 (en) 2011-03-23 2016-10-27 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
EP2756521A4 (en) 2011-09-16 2015-04-22 Univ Pennsylvania MODIFIED RNA T LYMPHOCYTES FOR THE TREATMENT OF CANCER
MY173865A (en) 2011-09-22 2020-02-25 Amgen Inc Cd27l antigen binding proteins
ES2861435T3 (en) * 2011-11-03 2021-10-06 Univ Pennsylvania Specific compositions of isolated B7-H4 and methods of using them
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
AR101936A1 (en) * 2014-07-31 2017-01-25 Amgen Res (Munich) Gmbh SPECIFIC BIESPECIFIC CHAIN ANTIBODY CONSTRUCTS SPECIFIED FOR OPTIMIZED CROSSED SPECIES
TWI717375B (en) * 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Antibody constructs for cd70 and cd3

Also Published As

Publication number Publication date
TWI785009B (en) 2022-12-01
EP3583129A1 (en) 2019-12-25
US12180292B2 (en) 2024-12-31
PT3583129T (en) 2021-12-14
ES2900233T3 (en) 2022-03-16
US11046775B2 (en) 2021-06-29
US20180230224A1 (en) 2018-08-16
US20210277132A1 (en) 2021-09-09
WO2018152181A1 (en) 2018-08-23
TW202321305A (en) 2023-06-01
EP3583129B1 (en) 2021-11-03
EP4008728A1 (en) 2022-06-08
TWI814525B (en) 2023-09-01
TW201833326A (en) 2018-09-16
TW202344517A (en) 2023-11-16

Similar Documents

Publication Publication Date Title
AR110979A1 (en) CD70 BINDING MOLECULES AND SAME USE METHODS
AR108066A1 (en) CHEMICAL RECEIVERS FOR CLL-1 AND METHODS OF USE OF THE SAME
PE20190120A1 (en) BINDING MOLECULES TO BCMA AND METHODS OF USE OF THEM
AR117727A1 (en) ANTIBODIES THAT JOIN CD3
AR106184A1 (en) PD-1 BINDING PROTEINS AND THEIR METHODS OF USE
AR127371A2 (en) CHIMERIC FLT3 RECEPTORS AND METHODS OF USING THEM
AR126242A2 (en) CANCER TREATMENT USING CHIMERIC ANTIGEN RECEPTORS
AR123876A2 (en) PHARMACEUTICAL COMPOSITION OF ANTI-CGRP ANTIBODIES
AR102698A1 (en) ANTIBODIES AGAINST CD73 AND ITS USES
PE20191463A1 (en) BISPECIFIC ANTIBODIES OF SPECIFIC JOINT PD1 AND LAG3
PE20180480A1 (en) FACTOR XI ANTIBODIES AND METHODS OF USE
AR111630A1 (en) ANTI-SIRPa ANTIBODIES
AR102554A1 (en) ANTI-CLDN ANTIGEN CHEMERIC RECEIVERS AND METHODS OF USE
AR106365A1 (en) BISPECIFIC MOLECULES OF ANTIGEN BINDING TO T-CELL ACTIVATORS
AR095980A1 (en) SPECIFIC BIESPECTIFIC ANTIBODIES FOR FAP (FIBROBLASTIC ACTIVATION PROTEIN) AND DR5 (DEATH RECEIVER 5), SPECIFIC ANTIBODIES FOR DR5 AND METHODS OF USE
AR096617A1 (en) ANTI-TWEAKR ANTIBODIES AND THEIR USES
AR102732A1 (en) T-CELL ACTIVATING ANTIGEN BINDING MOLECULES OF ANTIGEN
AR084141A1 (en) ANTI-CCL20 NEUTRALIZING ANTIBODIES
CL2018003072A1 (en) Humanized anti-basigin antibodies and their use.
AR109450A1 (en) ILT7 BINDING MOLECULES AND SAME USE METHODS
PE20220763A1 (en) MATERIALS AND METHODS FOR MODULATING T-CELL-MEDIATED IMMUNITY
PH12021550244A1 (en) Anti-btla antibody
PE20181956A1 (en) POLYPEPTIDES THAT INHIBIT CD40L
PE20191404A1 (en) GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USING THEM
PE20230306A1 (en) ANTIBODIES TARGETING A COMPLEX COMPRISING NON-CLASSIC HLA-I AND NEOANTIGEN AND THEIR METHODS OF USE

Legal Events

Date Code Title Description
FB Suspension of granting procedure